Evelo Biosciences, Inc. (Nasdaq:EVLO), Rutgers University, and Robert Wood Johnson University Hospital today announced the submission of an Investigational New Drug (IND) application for an Evelo-sponsored Phase 2 clinical study evaluating the safety and efficacy of EDP1815 for the treatment of hospitalized patients with newly diagnosed COVID-19. The study will be led by Reynold A. Panettieri, Jr., M.D., Vice Chancellor for Translational Medicine and Science at Rutgers Biomedical and Health Sciences and Professor of Medicine at Rutgers Robert Wood Johnson Medical School. To read the full story.
Home / News / Evelo Biosciences, Rutgers University, and Robert Wood Johnson University Hospital Announce Submission of IND for a Phase 2 Study of EDP1815 in COVID-19 Patients
Recent Posts
- NJACTS Community Engagement Core COVID-19 Resources
- Join NJ ACTS on 2/12 at 4pm for the Pilots Program 2026 Webinar
- NJACTS Community Engagement Core Available Services
- Mental Health and Pain Medication Prescriptions for Young People Have Declined in the Past 20 Years.
- Researchers Pitch Strategies to Identify Potential Fraudulent Participants in Online Qualitative Research.
Categories
- Community (2,439)
- Covid (997)
- CTO Events (6)
- News (3,088)
- Pilots (21)